Table 2.
Selected cancer vaccine studies
| Antigen | Phase | Disease | Technology | Co-therapy | Sponsor | Reference |
|---|---|---|---|---|---|---|
| NY-ESO-1 | I | Metastatic cancer | Recombinant protein | GLA -SE | Immune Design | NCT02015416 |
| I | Ovarian, fallopian tube cancer | DEC-205 Fusion protein | Poly-ICLC, IDO1 inhibitor | Roswell Park Cancer Institute | NCT02166905 | |
| I | NY-ESO-1 expressing solid tumors | DEC-205 Fusion protein/Dendritic ell | Rapamycin | Roswell Park Cancer Institute | NCT01522820 | |
| I/II | NY-ESO-1 expressing tumors | DEC-205 Fusion protein | Resiquimod, Poly-ICLC | Celldex Therapeutics | NCT00948961 | |
| I | NY-ESO-1 expressing tumors | Full length protein | Montanide, Resiquimod | Mount Sinai School of Medicine | NCT00821652 | |
| I | Ovarian, fallopian, primary peritoneal cancer | Peptide | Decitabine, Doxorubicin, Montanide | Roswell Park Cancer Institute | NCT01673217 | |
| I | NY-ESO-1/LAGE-1 expressing tumors | Peptide | CpG7909, Montanide | Ludwig Institute for Cancer Research | NCT00199836 | |
| I | Ovarian, fallopian, primary peritoneal cancer | Peptide | Montanide | Memorial Sloan Kettering Cancer Center | NCT00066729 | |
| I | Prostate cancer | Peptide | Baylor College of Medicine | NCT00616291 | ||
| I | Ovarian, fallopian, primary peritoneal cancer | Overlapping Long peptides (OLP4) | Montanide, Poly-ICLC | Ludwig Institute for Cancer Research | NCT00616941 | |
| I | Ovarian, fallopian, primary peritoneal cancer | Vector (ALVAC(2)-NY-ESO-1(M) TRICOM) | GM-CSF, Rapamycin | Roswell Park Cancer Institute | NCT01536054 | |
| I | Ovarian, fallopian, primary peritoneal cancer | Vector (ALVAC(2)-NY-ESO-1(M) TRICOM) | GM-CSF | Ludwig Institute for Cancer Research | NCT00803569 | |
| II | Ovarian, fallopian, primary peritoneal cancer | Vector (Fowlpox-NY-ESO-1) | Recombinant Vaccinia-NY-ESO_1 | Ludwig Institute for Cancer Research | NCT00112957 |